University of Nevada, Las Vegas
unlv.eduTotal trials
73
Active
21
Phase 3
0
Total enrollment
10,403
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 1 of 1 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Primary Ostomy Closure with 0.1% Betaine/0.1% Polyhexanide Wound Irrigation | — | — | — | — | — | 1 |
Next readouts
- 2028-12
Top conditions
- Parkinson Disease4
- Amputation4
- Down Syndrome3
- Neck Pain3
- Posttraumatic Stress Disorder3
- Inflammation Biomarkers3
- Obesity3
- Metabolic Syndrome3
Frequently asked questions about University of Nevada, Las Vegas
- How many clinical trials does University of Nevada, Las Vegas have on ClinicalTrials.gov?
- University of Nevada, Las Vegas is listed as the lead sponsor on 73 clinical trials in ClinicalTrials.gov, 21 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University of Nevada, Las Vegas's trials are in Phase 3?
- 0 of University of Nevada, Las Vegas's trials are in Phase 3, spread across 1 active drug program.
- What therapeutic areas does University of Nevada, Las Vegas focus on?
- University of Nevada, Las Vegas's most-studied conditions on ClinicalTrials.gov are Parkinson Disease, Amputation, Down Syndrome, Neck Pain, Posttraumatic Stress Disorder.
- When are University of Nevada, Las Vegas's next clinical trial readouts?
- University of Nevada, Las Vegas has 1 upcoming primary-completion readout tracked here; the soonest is “Ostomy Primary Closure With 0.1% Betaine/Polyhexanide Wound Irrigation Compared to Pursestring Closure”, expected around 2028-12.